Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a leader in innovative drug development and a vocal advocate for reducing ...

B. Riley raised the firm’s price target on Vanda Pharmaceuticals (VNDA) to $17 from $14 and keeps a Buy rating on the shares. Following BYSANTI’s approval, the firm’s revenue model for Vanda has been ...

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted the company's request for a formal evidentiary public hearing to review ...

A series of increasing buyout offers has failed to convince Vanda's board of directors that the company should sell itself. After receiving "unsolicited" buyout proposals from Michigan-based CDMO ...

Once again, Vanda Pharmaceuticals is challenging the FDA in court. This time, the company says the agency failed to give its application for Hetlioz in jet lag disorder a proper hearing after the FDA ...

Vanda said the FDA approved NEREUS (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion. The approval marks the first new pharmacologic ...

WASHINGTON, Dec. 20, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VGT-1849A, a selective ...

WASHINGTON, Feb. 20, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™ (milsaperidone) tablets, a ...

(RTTNews) - Vanda Pharmaceuticals Inc. (VNDA), a biopharmaceutical company announced on Monday, that it has accepted the FDA's offer for a hearing regarding its New Drug Application or NDA for ...

CEO Mihael Polymeropoulos reported "strong commercial execution with total net product sales reaching $56.3 million, up 18% year-over-year, led by a 31% increase in Fanapt sales and 35% growth in ...

Vanda asked Martin Makary, the Commissioner of the Food and Drug Administration, to review the decision made by Jacqueline Corrigan-Curay, the departing director of the FDA's Center for Drug ...

This morning Vanda, a global leader of high-frequency positioning data and tactical macro insights and Exante Data Inc, an innovative data analytics and global macro strategy provider announced they ...